Sorrento Therapeutics Inc
OTC:SRNE

Watchlist Manager
Sorrento Therapeutics Inc Logo
Sorrento Therapeutics Inc
OTC:SRNE
Watchlist
Price: 0.0035 USD Market Closed
Market Cap: $1.9m

Net Margin

-852.3%
Current
Improving
by 104.1%
vs 3-y average of -956.3%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-852.3%
=
Net Income
$-548m
/
Revenue
$64.3m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-852.3%
=
Net Income
$-548m
/
Revenue
$64.3m

Peer Comparison

Country Company Market Cap Net
Margin
US
Sorrento Therapeutics Inc
OTC:SRNE
1.9m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
394.7B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44.8B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...

Market Distribution

Lower than 93% of companies in the United States of America
Percentile
7th
Based on 15 072 companies
7th percentile
-852.3%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Sorrento Therapeutics Inc
Glance View

Market Cap
1.9m USD
Industry
Biotechnology

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. The company is headquartered in San Diego, California and currently employs 799 full-time employees. The company went IPO on 2007-01-19. The firm's segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. Sorrento's immuno-oncology platforms include key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS; and diagnostic test solutions, including COVITRACK and COVISTIX.

SRNE Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-852.3%
=
Net Income
$-548m
/
Revenue
$64.3m
What is Sorrento Therapeutics Inc's current Net Margin?

The current Net Margin for Sorrento Therapeutics Inc is -852.3%, which is above its 3-year median of -956.3%.

How has Net Margin changed over time?

Over the last 3 years, Sorrento Therapeutics Inc’s Net Margin has decreased from -760.8% to -852.3%. During this period, it reached a low of -1 104.6% on Mar 31, 2023 and a high of -495.1% on Mar 31, 2021.

Back to Top